MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST001090/mwtabprimaryOK200MetabolomicsNMRCancerHomo Sapienshttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST001090Treatment:No | Sensitivity:SensitiveTreatment:Yes | Sensitivity:SensitiveTreatment:No | Sensitivity:ResistantTreatment:Yes | Sensitivity:ResistantCultured CellsUniversity of Nebraska-LincolnNMR data.MetabolomicsWorkbench2'-Deoxy-2'-Difluorocytidine, (beta-D-threo-pentafuranosyl)-Isomer, 2'-DFDC, insensitive, Malignant Neoplasm, LY, 2'-Difluorodeoxycytidine, Neoplasms, Benign Neoplasm, Metabonomic, Metabonomics, Tumor, Malignant, LY 188011, LY-188011, dFdCyd, Gemcitabine Hydrochloride, MT, Benign, 2'-Deoxy-2', Hydrochloride, Neoplasm, 2'-Difluoro-2'-Deoxycytidine, 2' Deoxy 2' Difluorocytidine, Cell., 2', Metabolomic, study, Gemcitabine, primary cancer, resistant, Malignancy, Benign Neoplasms, (D-threo-pentafuranosyl)-Isomer, Cancers, 2' Deoxy 2', malignant tumor, Malignant Neoplasms, Neoplasias, Gemicitabine, malignant neoplasm, (alpha-D-threo-pentofuranosyl)-Isomer, 2'' Difluorocytidine 5' O Monophosphate, 188011, Malignancies, Gemzar, 2''-Difluorocytidine-5'-O-Monophosphate, Neoplasia, Cancer, TumorsfalseNMR metabolomics study of Gemcitabine resistant cancer cellsST0010909606